# Delix Therapeutics funding rounds and investors

As of 9 Nov 2026, Delix Therapeutics has raised $200M across 3 verified rounds on record; latest: $100 million Series C led by Johnson & Johnson and SV Health Investors’ Dementia Discovery Fund (DDF), announced 9 Nov 2026.

A clinical-stage neuroscience company pioneering the discovery and development of neuroplastogens

Website: https://delixtherapeutics.com  
Headquarters: Bedford, Mass.  
Page: https://fireround.dev/companies/delix-therapeutics

## Verified rounds

| Announced | Round | Amount | Lead investors | Other investors | Sources |
| --- | --- | --- | --- | --- | --- |
| 2026-11-09 | Series C | $100 million | Johnson & Johnson, SV Health Investors’ Dementia Discovery Fund (DDF) | Adage Capital Management, Artis Ventures, Bail Capital, Dolby Family Ventures, Hamilton Square Partners Management, LP (HSq), OMX Ventures, RA Capital Management, UC Investments, Vestal Point Capital, YK Bioventures | [businesswire.com](https://www.businesswire.com/news/home/20261109042682/en/Delix-Therapeutics-Closes-Oversubscribed-%24100-Million-Series-C-Financing-to-Advance-Zalsupindole-Into-Phase-II-Development-and-Finance-Broader-Pipeline-AdvancementExpansion), [morningstar.com](https://www.morningstar.com/news/business-wire/20261109042682/delix-therapeutics-closes-oversubscribed-100-million-series-c-financing-to-advance-zalsupindole-into-phase-ii-development-and-finance-broader-pipeline-advancementexpansion) |
| 2022-01-10 | Convertible | $30 million | not stated | none named | [delixtherapeutics.com](https://www.delixtherapeutics.com/news/delix-therapeutics-closes-30-million-convertible-note-financing-enters-10-million-strategic-credit-facility-option-in-partnership-with-comerica-bank), [prnewswire.com](https://www.prnewswire.com/news-releases/delix-therapeutics-closes-30-million-convertible-note-financing-enters-10-million-strategic-credit-facility-option-in-partnership-with-comerica-bank-301455628.html) |
| 2021-09-27 | Series A | $70 million | Artis Ventures, OMX Ventures, RA Capital Management | Apeiron, Bail Capital, Casa Verde Capital, Dolby Family Ventures, Negev Capital, Noetic Fund, Ocama Partners, Palo Santo, Presight Capital, PsyMed Ventures, R2, re.Mind Capital, Saya Bio, Vertical Ventures, WPSS | [prnewswire.com](https://www.prnewswire.com/news-releases/delix-therapeutics-closes-70-million-series-a-financing-to-advance-pipeline-of-novel-psychoplastogen-therapeutics-to-treat-brain-disorders-301385016.html), [fiercebiotech.com](https://www.fiercebiotech.com/biotech/delix-raises-70m-to-test-psychedelic-analogs-for-treating-brain-disorders-clinical-trials) |

Source: Fireround (https://fireround.dev), an open-source funding feed. Each round is checked against the pages listed with it.